Emtricitabine/Tenofovir Disoproxil Fumarate

Tier C — Watch / trade

Gilead Sciences Inc

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：RT, HIV-1 RT, HBV pol

Brand：Truvada

Indications (approved)：HIV infection

Regional status

Approved

2004-08-02

Approved

2005-02-20

China

Approved

2012-12-31

Japan

Approved

2005-03-23

Factories producing this API12

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

12 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Emtricitabine/Tenofovir Disoproxil Fumarate?

Approved indications include: HIV infection.

When does the Emtricitabine/Tenofovir Disoproxil Fumarate patent expire?

No public expiry year is available for Emtricitabine/Tenofovir Disoproxil Fumarate yet; this page updates once verified.

How do I get a quote for Emtricitabine/Tenofovir Disoproxil Fumarate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27